Morningstar

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...
ascopubs.org

Outcomes of additional BCG versus sequential gemcitabine + docetaxel in BCG-exposed high-risk non–muscle-invasive bladder cancer.

Clinical outcomes of chemotherapy with or without intravesical BCG in NMIBC patients: A Bayesian network meta-analysis. Baseline clinicopathologic variables of patients upon BCG exposed HR NMIBC ...

ImmunityBio Investors Rally Behind Cancer Trial Milestone

ImmunityBio Inc. IBRX shares are up during Thursday’s premarket session as the company has completed enrollment in its ...
ascopubs.org

Subsequent treatments and outcomes in bacillus Calmette-Guerin–unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world ...

Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC). Subsequent line of treatment for BCG unresponsive HR NMIBC patients ...